Progress and clinical potential of antibody-targeted therapy for arthritic damage.
The advent of biologic drugs like infliximab, Etanercept, rituximab and tocilizumab has greatly improved the treatment of rheumatoid arthritis, however, increased risk of infection and high cost still remain unmet needs. A new generation of targeted therapeutics is being developed to target payload drug specifically to arthritic tissue; to concentrate the drug in the disease area and limit the off target systemic exposure. This might also reduce total effective dose.



This article summarizes the properties and progress of targeted therapies that have been published on PubMed, and addresses their clinical potential. Expert commentary: Incredible progress with targeted therapies has already been made in the short time since the principle was first proven in animal models in 2007 when targeting payload drug to overexpressed oncofetal domain of fibronectin in inflamed arthritic joints.
a Clinical Neurosciences, Faculty of Medicine , University of Southampton , Southampton , United Kingdom.
Chris
C
Hughes
b Biochemical Pharmacology , Barts and The London School of Medicine and Dentistry, Queen Mary University of London , London , United Kingdom.
Ahuva
A
Nissim
D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068800:Etanercept / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D058990:Molecular Targeted Therapy
D061067:Antibodies, Monoclonal, Humanized; C502936:tocilizumab; D000068800:Etanercept
Rheumatoid arthritis; anti-ROS-CII; antibodies; cytokines; targeted therapeutics